Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e) Named Executive Officer Compensation
OnJanuary 25, 2023 , the Board of Directors ofSoleno Therapeutics, Inc. , (the "Company") following a review of the Company's executive compensation program by its Compensation Committee and recommendations, approved certain increases to the base salaries for fiscal year 2023, the payment of cash bonuses for fiscal year 2022 and certain equity awards for certain named executive officers as follows: Fiscal Year 2023 Annual Fiscal Year 2022 Cash Name and Principal Position Base Salary ($)(1 ) Bonus Award ($) Options(2)Anish Bhatnagar Chief Executive Officer $ 556,800 (3) $ 278,400 115,000 James Mackaness Chief Financial Officer $ 400,000 $ 154,000 30,000 Patricia Hirano Vice President of Regulatory Affairs $ 340,000 $ 97,800 20,000 Kristen Yen Vice President of Clinical Operations $ 325,000 $ 93,360 20,000
(1) Effective as of
(2) One forty-eighth (1/48th) of the shares subject to the Option shall vest on
the first month anniversary of
Date), and one forty-eighth (1/48th) of the total number of shares subject to
the Option shall vest each month thereafter on the same day of the month as
the Vesting Commencement Date.
(3) No change from Fiscal Year 2022 Annual Base Salary.
2
--------------------------------------------------------------------------------
© Edgar Online, source